Lipitor Study Creates More Doubts On CRP Study Used To Expand Crestor Label
Executive Summary
A new analysis of a large European trial presented at the American Heart Association annual meeting has further damaged the case for using C-reactive protein levels as a guide for statin therapy.
You may also be interested in...
Targeting Inflammation In Atherosclerosis After Darapladib: Does The IL-6 Pathway Hold The Answer?
Targeting inflammation appears to be a promising complementary approach to lipid-lowering drugs in atherosclerosis, but the question of which pathway in a complex system to target remains open. The failure of GlaxoSmithKline’s darapladib in the STABILITY trial may have dealt a fatal blow to phospholipase A2 enzymes as targets, but the interleukin-6 pathway is gaining attention with the ongoing CANTOS study of Novartis’ canakinumab and the NHLBI’s CIRT study of low-dose methotrexate.
Crestor Label Lends Validity To Controversial C-Reactive Protein Test
FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say
Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales
Company, however, reaffirms EPS guidance for the year.